Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO
PR Newswire Asia
BEIJING and SHANGHAI and CHICAGO, June 2, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing..
BEIJING and SHANGHAI and CHICAGO, June 2, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing..
BERKELEY, Calif. and MAINZ, Germany, May 31, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics..
· Phase 3 CARES-310 study found combination of camrelizumab and rivoceranib continued to show sustained long-term survival..